Aclaris Therapeutics (ACRS) Tops Q1 EPS by 2c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.12), $0.02 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.46 million versus the consensus estimate of $4.09 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Goldman Sachs Reinstates Estee Lauder (EL) at Buy
• Stocks expected to have increasing option volume: SPCX FDX CCL MU ABBV APGE MTN